Actively Recruiting

Age: 7Years - 18Years
All Genders
ID04602325

Systemic Biomarkers of Brain Injury From Hyperammonemia in Inherited Metabolic Disorders and Related Conditions

Led by Children's National Research Institute · Updated on 2024-02-07

24

Participants Needed

1

Research Sites

43 weeks

Total Duration

On this page

Sponsors

C

Children's National Research Institute

Lead Sponsor

N

National Center for Advancing Translational Sciences (NCATS)

Collaborating Sponsor

AI-Summary

What this Trial Is About

This research investigates brain injury biomarkers in patients with inherited hyperammonemic disorders and other metabolic conditions. High ammonia levels in the blood can harm the brain, causing swelling, blood vessel problems, intellectual disabilities, and in severe cases, coma or death. The study aims to understand the timing of brain injury markers during hyperammonemic episodes and to explore these markers in other metabolic diseases like Maple Syrup Urine Disease and Glutaric Acidemia. Participants include those diagnosed with specific urea cycle disorders, organic acidemias, fatty acid oxidation disorders, or hypoxic-ischemic encephalopathy. The study involves collecting and analyzing blood samples for biomarkers S100B, NSE, and UCHL1 during hospital stays and outpatient visits. These measurements will track biomarker changes alongside blood ammonia levels and neurological status. Patients will be enrolled during hospitalizations or preferably at outpatient visits, where leftover blood samples from routine tests are used. Biomarker levels will be measured sequentially during hospital stays until ammonia and mental status normalize, and again at follow-up outpatient visits to assess recovery. Researchers will monitor biomarker patterns over up to two years to better understand brain injury progression and recovery in these conditions.

CONDITIONS

Brief Title

Systemic Biomarkers of Brain Injury From Hyperammonemia

Who Can Participate

Age: 7Years - 18Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 7 and 18 years
  • Diagnosis of one of seven urea cycle disorders: NAGS, CPSD, OTCD, ASD, ALD, AD, or HHH
  • Diagnosis of one of two organic acidemias: Propionic Acidemia or Methylmalonic Acidemia
  • Diagnosis of Maple Syrup Urine Disease or Glutaric Acidemia (GA1) with neurological effects
  • Diagnosis of fatty acid oxidation disorders including Medium Chain-Acyl CoA Dehydrogenase Deficiency, Very Long Chain-Acyl CoA Dehydrogenase Deficiency, Trifunctional Protein Deficiency, Long Chain Hydroxyacyl-CoA Dehydrogenase Deficiency, Carnitine Palmitoyltransferase I or II Deficiency, Carnitine/Acylcarnitine Translocase Deficiency, or Primary Carnitine Transport Deficiency
  • Diagnosis of hypoxic-ischemic encephalopathy
Not Eligible

You will not qualify if you...

  • Prior solid-organ transplant
  • Use of any other investigational drug, biologic, or therapy
  • Any clinical or laboratory abnormality or medical condition that may interfere with biomarker measurements as determined by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Monitoring

Duration - Up to 2 years

Participants have blood samples collected from discarded laboratory tests during outpatient visits and hospitalizations to measure biomarkers of brain injury and ammonia levels.

Visits during hospitalizations and outpatient visits as clinically indicated

Long-term Monitoring

Duration - Up to 2 years

Participants are followed up after hospitalization to determine if biomarker levels return to baseline during subsequent outpatient visits.

Visits during outpatient follow-up as clinically indicated

Trial Site Locations

Total: 1 location

1

Children's National Research Institute

Washington D.C., District of Columbia, United States, 20010

Actively Recruiting

Loading map...

Research Team

K

Katie Rice, MPH, CCRP

N

Nicholas Ah Mew, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

4

Similar Trials

A Phase IIb Dose Escalation Study of Levetiracetam for the T...

Neonatal Seizure

Actively Recruiting

5 locations

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study...

Hypoxic-Ischemic Encephalopathy

Actively Recruiting

15 locations

A Multicenter, Randomized, Double-blind, Placebo-controlled ...

Hypoxic-Ischemic Encephalopathy

Actively Recruiting

4 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here